ID

31028

Description

Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Please record all prior therapies for NHL (e.g. chemotherapy, immunotherapy, steroidal therapy).

Keywords

  1. 7/12/18 7/12/18 -
Copyright Holder

see clinicaltrials.gov

Uploaded on

July 12, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755

Prior Therapy

  1. StudyEvent: ODM
    1. Prior Therapy
Administrative Data
Description

Administrative Data

Alias
UMLS CUI-1
C1320722
Site Number
Description

Site number

Data type

text

Alias
UMLS CUI [1,1]
C0018704
UMLS CUI [1,2]
C0600091
Patient Number
Description

Patient Number

Data type

text

Alias
UMLS CUI [1]
C1830427
Patient Initials
Description

Patient Initials

Data type

text

Alias
UMLS CUI [1]
C2986440
xxx
Description

xxx

Chemotherapy Code
Description

Chemotherapy Code

Data type

text

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0600091
Drugs (list drug names only if no code is given)
Description

Chemotherapy, Pharmaceutical preparations

Data type

text

Alias
UMLS CUI [1,1]
C1302181
UMLS CUI [1,2]
C0013227
Start Date
Description

Chemotherapy Start Date

Data type

date

Alias
UMLS CUI [1,1]
C1302181
UMLS CUI [1,2]
C0808070
Stop Date
Description

Chemotherapy End Date

Data type

date

Alias
UMLS CUI [1,1]
C1302181
UMLS CUI [1,2]
C0806020
Number of Cycles
Description

Number of Cycles

Data type

integer

Alias
UMLS CUI [1]
C2045831
Therapy Outcome
Description

Chemotherapy, Outcome of Therapy

Data type

text

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1518681
Duration of Response
Description

Chemotherapy, Response Duration

Data type

integer

Measurement units
  • months
Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0237585
months

Similar models

Prior Therapy

  1. StudyEvent: ODM
    1. Prior Therapy
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
Site number
Item
Site Number
text
C0018704 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Patient Number
Item
Patient Number
text
C1830427 (UMLS CUI [1])
Patient Initials
Item
Patient Initials
text
C2986440 (UMLS CUI [1])
Item Group
Chemotherapy Code
Item
Chemotherapy Code
text
C0392920 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Chemotherapy, Pharmaceutical preparations
Item
Drugs (list drug names only if no code is given)
text
C1302181 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
Chemotherapy Start Date
Item
Start Date
date
C1302181 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
Chemotherapy End Date
Item
Stop Date
date
C1302181 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Number of Cycles
Item
Number of Cycles
integer
C2045831 (UMLS CUI [1])
Item
Therapy Outcome
text
C0392920 (UMLS CUI [1,1])
C1518681 (UMLS CUI [1,2])
Code List
Therapy Outcome
CL Item
CR (CR)
CL Item
CCR (CCR)
CL Item
PR (PR)
CL Item
SD (SD)
CL Item
PD (PD)
CL Item
Unknown (Unknown)
Chemotherapy, Response Duration
Item
Duration of Response
integer
C0392920 (UMLS CUI [1,1])
C0237585 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial